SAFETY OF INOTERSEN TREATMENT IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Noel R. Dasgupta(Ionis Pharmaceuticals (United States)), Stephen B. Heitner(Brigham and Women's Hospital), John L. Berk(Boston University), Jesse Kwoh(Ionis Pharmaceuticals (United States)), Márcia Waddington‐Cruz(Université Paris-Sud), Mazen Hanna(Cleveland Clinic), Matthew J. Maurer(Mayo Clinic in Arizona), Carol Whelan(The Royal Free Hospital), Thomas H. Brannagan(Columbia University), Isabel Conceição(Université Paris-Sud), Brian Drachman(Penn Presbyterian Medical Center), Thibaud Damy(Amyloidosis Foundation), Rodney H. Falk(Brigham and Women's Hospital), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Spencer Guthrie(Heidelberg University), Giampaolo Merlini(University of Pavia), Teresa Coelho(Universidade do Porto), Merrill D. Benson(Indiana University School of Medicine), Shiangtung W. Jung(Université Paris-Sud), Michael Pollock(McMaster University), Morie A. Gertz(Medical University of South Carolina)
Cited by 7
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k